BIOLASE, Inc. Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement

Stock Information for Acer Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Acer Therapeutics Inc.

Biolase Reports Full-Year 2023 Results; Expects Continued Revenue Growth In 2024
BIOLASE to Report Fourth Quarter and Full Year 2023 Results on March 21, 2024
Biolase Announces First Quarter 2024 Webinar Series 'Lets Talk Dental'
BIOLASE, Inc. Announces Closing of $7.0 Million Public Offering
BIOLASE REPORTS UNAUDITED REVENUE GROWTH FOR FULL YEAR 2023 AND PROVIDES OUTLOOK FOR FULL YEAR 2024
BIOLASE ENHANCES EDUCATION OFFERINGS IN 2024 DUE TO INCREASING DEMAND OF DENTAL LASER COURSES THROUGHOUT 2023
BIOLASE RECEIVES SECOND TOP WORKPLACES 2023 AWARD
BIOLASE RECEIVES TOP WORKPLACES 2023 AWARD

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.